Reversible Severe Mitral Regurgitation During Immunotherapy in a Structurally Vulnerable Valve: A Case Report

Clicks: 1
ID: 318921
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #221 of 251 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 251 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background T-cell therapy (TCT) rarely causes isolated severe valvular pathology without cardiomyopathy, but its hemodynamic effects can exacerbate mitral regurgitation (MR) in patients with subtle valvular issues, and reports describing reversible valvular dysfunction in this context remain limited. Case A 48-year-old woman with a history of fenfluramine (FF) use for weight loss ten years prior was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). Baseline echocardiogram revealed trace MR. After her second blinatumomab (BL) cycle, she developed acute heart failure symptoms. Repeat echocardiogram showed severe MR with posterior leaflet restriction. Systemic inflammatory symptoms and end-organ damage were notably absent. BL was held, and medical therapy for heart failure with preserved ejection fraction (HFpEF) was initiated, improving MR and allowing resumption of BL. Decision-making Baseline posterior mitral leaflet restriction was likely related to prior FF use. While BL carries a low cardiotoxicity profile, it can cause heart failure via cytokine release syndrome (CRS)-dependent and potentially CRS-independent pathways. In this case, we hypothesize that transient elevations in left-sided filling pressures, possibly from unmasking subtle diastolic dysfunction in a structurally vulnerable valve, amplified her MR. Delayed disclosure of FF use underscores the importance of intentional, non-judgmental history-taking. Recognition of this interaction guided hemodynamic optimization and enabled cautious, successful reinitiation of BL therapy. Conclusion We emphasize considering prior FF use when evaluating patients with idiopathic MR. We also demonstrate how hemodynamic changes from TCT can worsen MR and show how careful hemodynamic management can enable the safe resumption of this lifesaving therapy.
Reference Key
openalex_W7166016092 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sachin Singh, Ushma Majmudar, Indu Poornima, Anita Radhakrishnan
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag474
URL
https://doi.org/10.1093/ehjcr/ytag474
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.